Search clinical trials for: Salmeterol 50mcg/ Fluticasone Propionate 500mcg

Total 867 results

GlaxoSmithKline

Completed

GSK BHR Study (Sont - Second Study)

Asthma

United States, Bulgaria, Puerto Rico, Brazil
GlaxoSmithKline

Completed

GSK BHR Study (Sont)

Asthma

United States, Latvia, Puerto Rico, Brazil
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Sandoz

Completed

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

Asthma

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
The First Affiliated Hospital with Nanjing Medical University; Cancer Institute... and other collaborators

Unknown

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia (PEG-rhG-CSF)

Neutropenia

China
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
GlaxoSmithKline
Parexel

Completed

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI)

Asthma

United States, Australia, Poland, Russian Federation, Spain, Ukraine, Germany, Bulgaria, Argentina, Peru, South Africa, Taiwan, Belgium, Italy, Hungary, Korea, Republic of, Austria, Romania, Colombia, Slovakia, United Kingdom, Mexico and more
GlaxoSmithKline

Completed

A Healthy Volunteer Study With Inhaled GSK573719 and Placebo

Pulmonary Disease, Chronic Obstructive

Belgium
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
GlaxoSmithKline
Parexel

Completed

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI)

Asthma

United States, Australia, Spain, Taiwan, Bulgaria, Russian Federation, Ukraine, Argentina, Germany, Peru, Poland, South Africa, Thailand, Korea, Republic of, Austria, Belgium, Hungary, Italy, Slovakia, Malaysia, Czechia, Mexico, United... and more
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Ukraine, Spain, South Africa, Italy
BioNTech SE
Pfizer

Completed

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

SARS-CoV-2 Infection, COVID-19

United States, Spain, Finland, Poland, Mexico, Brazil
Daewoong Bio Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects

Dry Eye Syndromes

Korea, Republic of
GlaxoSmithKline

Completed

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Asthma

Russian Federation, United States, Peru, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Inmagene LLC

Recruiting

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

Hiv

United States
GlaxoSmithKline

Completed

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Pulmonary Disease, Chronic Obstructive

Japan
Jiangsu Province Centers for Disease Control and...
Shenzhen Kangtai Biological Products Co., LTD

Completed

The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

Hepatitis b
GlaxoSmithKline

Completed

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Pulmonary Disease, Chronic Obstructive

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
GlaxoSmithKline

Completed

Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Estonia, Denmark, Spain, Finland, Slovakia, United Kingdom, Italy, Lithuania
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
Eurofarma Laboratorios S.A.

Withdrawn

Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis (RINEX50)

Rhinitis, Allergic, Perennial

Brazil
University of California, Davis
Washington University School of Medicine

Terminated

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive (ROBI)

Uterine Bleeding Heavy | Abnormal Uterine Bleeding, Unspecified

United States
Shandong Luoxin Pharmaceutical Group Stock Co.,...

Completed

A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

Healthy

China
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Knee Osteoarthritis

United States
GlaxoSmithKline

Completed

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Asthma

Germany, Romania, Bulgaria, Chile, Russian Federation, South Africa, Estonia, Italy, Mexico, Greece, Hungary, Croatia, Brazil
GlaxoSmithKline

Completed

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Russian Federation, Sweden, United Kingdom
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
GlaxoSmithKline

Completed

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Healthy Person

China
Dey

Completed

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Bronchial Asthma

Japan
BiondVax Pharmaceuticals ltd.

Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

Influenza

Israel
Bristol-Myers Squibb

Completed

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Hepatic Insufficiency

United States
Yuhan Corporation

Completed

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of

3

Subscribe